LifeMD, Inc. (NASDAQ:LFMD) Receives Average Rating of “Moderate Buy” from Analysts

LifeMD, Inc. (NASDAQ:LFMD) has earned an average rating of “Moderate Buy” from the ten brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $9.1429.

LFMD has been the subject of several research analyst reports. Weiss Ratings raised LifeMD from a “sell (e+)” rating to a “sell (d)” rating in a report on Thursday, May 7th. Cantor Fitzgerald reissued an “overweight” rating on shares of LifeMD in a research note on Tuesday, March 10th. Wall Street Zen raised LifeMD from a “sell” rating to a “hold” rating in a research note on Saturday, June 20th. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of LifeMD in a research note on Tuesday, May 26th. Finally, BTIG Research restated a “buy” rating and set a $10.00 price objective on shares of LifeMD in a research report on Monday, May 4th.

Hedge Funds Weigh In On LifeMD

Institutional investors have recently bought and sold shares of the stock. Federated Hermes Inc. raised its holdings in LifeMD by 278.1% in the 4th quarter. Federated Hermes Inc. now owns 980,285 shares of the company’s stock worth $3,343,000 after acquiring an additional 721,018 shares during the period. Prescott Group Capital Management L.L.C. acquired a new stake in LifeMD during the fourth quarter worth $2,344,000. Arrowstreet Capital Limited Partnership increased its stake in LifeMD by 1,767.8% in the second quarter. Arrowstreet Capital Limited Partnership now owns 434,937 shares of the company’s stock valued at $5,924,000 after acquiring an additional 411,651 shares during the period. JPMorgan Chase & Co. grew its stake in shares of LifeMD by 581.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 412,571 shares of the company’s stock valued at $5,619,000 after purchasing an additional 352,004 shares during the period. Finally, Whetstone Capital Advisors LLC raised its stake in LifeMD by 89.6% during the fourth quarter. Whetstone Capital Advisors LLC now owns 703,053 shares of the company’s stock worth $2,397,000 after acquiring an additional 332,269 shares in the last quarter. 35.52% of the stock is currently owned by institutional investors.

LifeMD Price Performance

LFMD opened at $4.54 on Thursday. LifeMD has a 12 month low of $2.56 and a 12 month high of $13.23. The business has a 50-day moving average of $4.56 and a two-hundred day moving average of $3.87. The stock has a market capitalization of $219.55 million, a price-to-earnings ratio of 90.82 and a beta of 1.99.

LifeMD (NASDAQ:LFMD) last issued its earnings results on Wednesday, May 6th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.06). The firm had revenue of $50.16 million during the quarter, compared to analyst estimates of $48.84 million. LifeMD had a net margin of 2.37% and a negative return on equity of 150.88%. Equities research analysts anticipate that LifeMD will post -0.37 earnings per share for the current year.

LifeMD Company Profile

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.